<DOC>
	<DOCNO>NCT00671476</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin hydrochloride liposome , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This clinical trial study side effect doxorubicin hydrochloride liposome see well work treat woman ductal carcinoma situ undergo surgery .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Liposome Treating Women With Ductal Carcinoma Situ Undergoing Surgery</brief_title>
	<detailed_description>OBJECTIVES : - To demonstrate efficacy safety neoadjuvant intraductal pegylated liposomal doxorubicin hydrochloride woman ductal breast carcinoma situ undergo surgery . - To demonstrate ability identify cannulate duct demonstrate precancerous disease woman . - To integrate Humboldt Community Breast Health Project plan execution study . OUTLINE : Patients undergo identification intraductal lesion via cannulization . Patients receive pegylated liposomal doxorubicin hydrochloride ( PLD ) intraductally insert cannula . Some patient randomize receive saline instead PLD . Within 4-6 week , patient undergo surgery . Patients undergo tissue ductal fluid sample collection baseline surgery correlative laboratory study . Tissue sample assess histomorphology , proliferation ( Ki67 ) , cell death ( apoptosis index ) , genetic marker , necrosis , inflammation , loss heterozygosity HE stain , IHC , TUNEL , PCR . Nipple aspirate ductal lavage fluid sample analyze cytomorphology ( cellular atypia ) , proliferation ( Ki67 ) , cell death ( TUNEL ) , differentiation ( G-actin ) , genetic marker ( FISH ) quantitative fluorescence image analysis . Samples also analyze bFGF CEA ELISA , methylation PCR . After completion study therapy , patient follow every 6 month least 2 year .</detailed_description>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ductal breast carcinoma situ core needle biopsy No pathological invasive microinvasive disease affect breast Mammographic microcalcifications limit one ductal system one quadrant breast Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify Must able undergo necessary surgery Not pregnant PRIOR CONCURRENT THERAPY : No prior surgery radiotherapy recently diagnose breast More 12 month since prior chemotherapy No prior subareolar breast surgery affect breast Not concurrently involve research protocol unapproved new drug evaluation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>